Ugrás a tartalomra
Merck

SML2092

Sigma-Aldrich

R115866

≥98% (HPLC)

Szinonimák:

(B)-N-[4-[2-Ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl]-2-benzothiazolamine, (R)-N-[4-[2-Ethyl-1-(1H-1,2,4-triazol(-1-yl)butyl]phenyl]-2-benzothiazolamine, TLZ, Talarozole

Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez


About This Item

Tapasztalati képlet (Hill-képlet):
C21H23N5S
CAS-szám:
Molekulatömeg:
377.51
MDL-szám:
UNSPSC kód:
12352200
NACRES:
NA.77

Teszt

≥98% (HPLC)

Forma

film

szín

colorless

oldhatóság

DMSO: 2 mg/mL, clear

tárolási hőmérséklet

2-8°C

SMILES string

[s]1c2c(nc1Nc3ccc(cc3)[C@H]([n]4ncnc4)C(CC)CC)cccc2

InChI

1S/C21H23N5S/c1-3-15(4-2)20(26-14-22-13-23-26)16-9-11-17(12-10-16)24-21-25-18-7-5-6-8-19(18)27-21/h5-15,20H,3-4H2,1-2H3,(H,24,25)/t20-/m1/s1

Nemzetközi kémiai azonosító kulcs

SNFYYXUGUBUECJ-HXUWFJFHSA-N

Biokémiai/fiziológiai hatások

Orally active retinoic acid (RA) metabolism blocking agent (RAMBA) with higher CYP26 specificity and potency than liarozole (R75251).
R115866 (Talarozole) is an orally active all-trans retinoic acid (RA) metabolism blocking agent (RAMBA; IC50 = 4 nM against RA metablism in yeast microsomes expressing human CYP26) with much reduced or little potency against CYP19 (aromatase), CYP17 (17,20-lyase), CYP2C11, CYP3A, and CYP2A1 (IC50 from 1.2 to >10 μM). Plasma and tissue RA upregulation via R115866 oral treatment exhibits in vivo efficacy in several retinoid-responsive rodent models, including vaginal keratinization suppression (ED50 = 1.0 mg/kg/day vs. 5.1 mg/kg/day with RA in rats), pinnal hyperplasia induction (ear epidermis thickness = 35.5 μm with 2.5 mg/kg/day R115866 vs. 16.5 μm in control mice), conversion of caudal para- to ortho-keratosis (90% with 1.25 mg/kg/day R115866 vs. 30.3% in control mice). Comparing to liarozole, R115866 is CYP26-selective and does not inhibit CYP-mediated biosynthesis of adrenal and gonadal steroid hormones.

Tárolási osztály kódja

11 - Combustible Solids

WGK

WGK 3

Lobbanási pont (F)

Not applicable

Lobbanási pont (C)

Not applicable


Válasszon a legfrissebb verziók közül:

Analitikai tanúsítványok (COA)

Lot/Batch Number

Nem találja a megfelelő verziót?

Ha egy adott verzióra van szüksége, a tétel- vagy cikkszám alapján rákereshet egy adott tanúsítványra.

Már rendelkezik ezzel a termékkel?

Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.

Dokumentumtár megtekintése

Sasmita Tripathy et al.
Molecular pharmacology, 89(5), 560-574 (2016-02-28)
All-trans-retinoic acid (atRA) is the active metabolite of vitamin A. The liver is the main storage organ of vitamin A, but activation of the retinoic acid receptors (RARs) in mouse liver and in human liver cell lines has also been
Salvador Alonso et al.
The Journal of clinical investigation, 126(12), 4460-4468 (2016-10-25)
Interactions between multiple myeloma (MM) cells and the BM microenvironment play a critical role in bortezomib (BTZ) resistance. However, the mechanisms involved in these interactions are not completely understood. We previously showed that expression of CYP26 in BM stromal cells
Sonia Guidato et al.
Molecular and cellular neurosciences, 23(1), 81-95 (2003-06-12)
Motor neurons are found throughout the developing chick hindbrain, while somatic motor (SM) neurons develop only in rhombomeres 5 to 8 (r5-8), and in r1. In r2-8 neuroepithelial explants from stage 7-10 embryos cultured in collagen gels, we found that
João E Carvalho et al.
BMC evolutionary biology, 17(1), 24-24 (2017-01-21)
During embryogenesis, tight regulation of retinoic acid (RA) availability is fundamental for normal development. In parallel to RA synthesis, a negative feedback loop controlled by RA catabolizing enzymes of the cytochrome P450 subfamily 26 (CYP26) is crucial. In vertebrates, the
Philippe Diaz et al.
Journal of medicinal chemistry, 59(6), 2579-2595 (2016-02-27)
Cytochrome P450 CYP26 enzymes are responsible for all-trans-retinoic acid (atRA) clearance. Inhibition of CYP26 enzymes will increase endogenous atRA concentrations and is an attractive therapeutic target. However, the selectivity and potency of the existing atRA metabolism inhibitors toward CYP26A1 and

Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.

Lépjen kapcsolatba a szaktanácsadással